Key Takeaways
- • Private equity deal value in medtech nearly doubled year-over-year in 2025 to approximately $33 billion, with deal volume climbing nearly 20%, signaling aggressive PE capital deployment in the sector.
- • Healthcare private equity broadly delivered record performance in 2025, with disclosed deal value exceeding an estimated $191 billion globally, demonstrating a marked resurgence in PE activity across the healthcare ecosystem.
- • Medtech sector fundamentals remain robust, with industry revenue growth stabilizing 1–1.5% above prepandemic rates, driven by aging demographics, rising chronic disease prevalence, and an acceleration in FDA-approved innovations including AI-enabled medical devices.
- • Private equity firms are capitalizing on medtech's dual tailwinds of resilient market demand (U.S. healthcare spending growing ~5% annually) and record innovation pipelines, positioning PE as a dominant consolidating force in medical device manufacturing.
- • PE investors are targeting medtech companies capable of rapid scaling and market share capture through technology adoption, digital health solutions, and novel innovation in high-growth areas including surgical robotics, cardiovascular devices, and digital therapeutics.
Summary
Private equity has emerged as a dominant force in medtech investment, with 2025 marking a watershed moment for PE activity in the medical device sector. PE-backed medtech deal value nearly doubled year-over-year to an estimated $33 billion in 2025, while deal volume increased approximately 20%, according to available market research. This acceleration reflects broader momentum in healthcare private equity, which delivered record global performance in 2025 with disclosed deal value exceeding an estimated $191 billion, surpassing prior benchmarks and signaling a decisive resurgence in PE dealmaking across healthcare.
The investment thesis driving PE interest in medtech is anchored in favorable structural market conditions. Medtech revenues have stabilized at growth rates 1–1.5% above prepandemic norms, supported by strong healthcare fundamentals including U.S. health spending growth of approximately 5% annually. Demographic tailwinds—particularly an aging population and rising prevalence of chronic diseases—are expanding the addressable market for medical devices and digital health solutions. Simultaneously, patient access patterns are shifting toward outpatient and home-based care settings, creating incremental demand for remote monitoring and ambulatory care technologies.
Innovation velocity is accelerating across the medtech landscape, further enhancing investment appeal. In 2023, the FDA approved a record number of novel medical technologies, including an unprecedented volume of AI-enabled devices. The innovation pipeline spans high-growth domains including cardiovascular devices, surgical robotics, digital therapeutics, and neuromodulation. Industry experts anticipate that large, transformative innovations—rather than incremental improvements—will increasingly drive commercial success and valuation expansion.
PE investors are strategically targeting medtech firms positioned to leverage these technological and demographic trends for rapid scaling and market share consolidation. Private equity's capital, operational resources, and consolidation expertise have become integral to the medical device manufacturing ecosystem, with PE backing now a defining characteristic of M&A activity in the sector. For medtech business owners and management teams, the current PE appetite represents a compelling exit environment, with institutional capital actively competing for quality assets in growth and buyout stages across the medical device value chain.
The investment thesis driving PE interest in medtech is anchored in favorable structural market conditions. Medtech revenues have stabilized at growth rates 1–1.5% above prepandemic norms, supported by strong healthcare fundamentals including U.S. health spending growth of approximately 5% annually. Demographic tailwinds—particularly an aging population and rising prevalence of chronic diseases—are expanding the addressable market for medical devices and digital health solutions. Simultaneously, patient access patterns are shifting toward outpatient and home-based care settings, creating incremental demand for remote monitoring and ambulatory care technologies.
Innovation velocity is accelerating across the medtech landscape, further enhancing investment appeal. In 2023, the FDA approved a record number of novel medical technologies, including an unprecedented volume of AI-enabled devices. The innovation pipeline spans high-growth domains including cardiovascular devices, surgical robotics, digital therapeutics, and neuromodulation. Industry experts anticipate that large, transformative innovations—rather than incremental improvements—will increasingly drive commercial success and valuation expansion.
PE investors are strategically targeting medtech firms positioned to leverage these technological and demographic trends for rapid scaling and market share consolidation. Private equity's capital, operational resources, and consolidation expertise have become integral to the medical device manufacturing ecosystem, with PE backing now a defining characteristic of M&A activity in the sector. For medtech business owners and management teams, the current PE appetite represents a compelling exit environment, with institutional capital actively competing for quality assets in growth and buyout stages across the medical device value chain.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.